Related Experiment Video

Updated: Oct 2, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia

Joseph P Lynch III1, Fernando J Martinez

  • 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, 48109, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|January 26, 2002
PubMed

Insights

Macrolide resistance in Streptococcus pneumoniae is rising globally, driven by genetic mutations and prior antibiotic use. Despite concerns, clinical impact may be limited due to macrolide properties.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Macrolides are frontline treatments for community-acquired pneumonia.
  • Increasing macrolide resistance in Streptococcus pneumoniae is a significant global health concern.
  • Resistance mechanisms include ribosomal target site mutations (ermAM) and active drug efflux (mefE).

Purpose of the Study:

  • To review the prevalence, risk factors, and mechanisms of macrolide resistance in Streptococcus pneumoniae.
  • To discuss the clinical implications of macrolide resistance on pneumonia treatment outcomes.
  • To explore therapeutic strategies and future directions in managing macrolide-resistant pneumococcal infections.

Main Methods:

  • Literature review of studies on macrolide resistance in Streptococcus pneumoniae.
  • Analysis of genetic mechanisms (ermAM, mefE) and epidemiological data.
  • Assessment of clinical outcome data and pharmacokinetic/pharmacodynamic properties.

Main Results:

  • Macrolide resistance in S. pneumoniae is escalating worldwide, with prior antibiotic exposure as a key risk factor.
  • Genetic mutations (ermAM, mefE) are primary drivers of resistance.
  • Limited data exist on clinical outcomes, but some experts suggest impact may be minimal due to drug properties.

Conclusions:

  • The rise in macrolide resistance necessitates ongoing surveillance and strategic management.
  • Understanding resistance mechanisms and host factors is crucial for effective treatment.
  • Further research is needed to fully elucidate the clinical impact of macrolide resistance and optimize therapeutic approaches.

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: